June 9, 2014 | According to a “Globes” report, VBL Therapeutics (formerly known as Vascular Biogenics) announced that it will file for a $75 million initial public offering (IPO) on Nasdaq. The company will reportedly also offer an option for underwriter overallotment, or the issuing of 15 percent more shares, for the underwriters Deutsche Bank Securities, Wells Fargo, JP Morgan and Oppenheimer. Founded in 2000, VBL Therapeutics is developing drugs for the treatment of brain cancer and inflammatory diseases and has raised $100 million in investments.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
![](https://nocamels.com/wp-content/uploads/2018/02/INSIGHTEC-350x180.jpg)
Israeli Ultrasound Creator Collaborating On Neuroscience R&D In US
September 05, 2024
![The Weizmann Institute of Science. Photo via the Weizmann Institute of Science](https://nocamels.com/wp-content/uploads/2018/07/weizmann-350x252.jpg)
Weizmann In World’s Top 10 For Biomedical And Overall Research
September 05, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/Depositphotos_75148477_L-350x228.jpg)
Israeli NGO Begins New Mental Health Training In Ukraine
September 04, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/17123254699_79ff768811_ks-350x213.jpg)
Nonprofit Launches Loans For Stricken Northern Israel Businesses
September 04, 2024
Facebook comments